Live Chat ×
Skip to main content

Mutations in MDS - Prognostic and Therapeutic Implications

Thank you

This live web event has ended. Thank you for attending.

Contributors

  • Amer Zeidan, MD

    Dr. Amer Zeidan is an Assistant Professor of Medicine (Hematology) at Yale University. He completed a hematology/oncology fellowship and a clinical research fellowship in myelodysplastic syndromes (MDS) at Johns Hopkins University where he also earned a Master of Health Science (MHS) degree in Clinical Investigation. Dr. Zeidan received his MBBS degree from the Faculty of Medicine, University of Jordan in Amman, Jordan before completing his internal medicine residency at Rochester General Hospital in Rochester, New York. Dr. Zeidan specializes in the management of MDS and acute myeloid leukemia (AML). He is a nationally recognized expert in the clinical management of these diseases and is a member of the National Comprehensive Cancer Network (NCCN) clinical guideline panel for MDS. The focus of Dr. Zeidan’s clinical/translational research is the development of novel therapies for MDS, AML, and other hematologic malignancies. He is the principal investigator on several clinical trials in MDS, AML, and other hematologic malignancies. Dr. Zeidan especially focuses on the use of immunotherapies including immune checkpoint inhibitors for myeloid malignancies.

April 18, 2019
Thu 2:30 PM EDT

Duration 1H 0M

This live web event has ended.